Global Vero Cell Rabies Vaccines for Human Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Vero Cell Rabies Vaccines for Human Market Research Report 2024
According to Mr Accuracy reports new survey, global Vero Cell Rabies Vaccines for Human market is projected to reach US$ 1199.6 million in 2029, increasing from US$ 653 million in 2022, with the CAGR of 0.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Vero Cell Rabies Vaccines for Human market research.
Based on the culture medium, human rabies vaccines can be divided into vero cell vaccines, hamster kidney cell vaccines, chicken embryo cell vaccines and human diploid cell vaccines according to the culture medium. Developed countries in Europe and the United States mainly use human diploid cell vaccines , and China mainly uses second-generation vero cell vaccines.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Vero Cell Rabies Vaccines for Human market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bharat Biotech
Sanofi-Pasteur
Chengda Bio
Prcmise
Zhuoyi Biological
Ningbo Rongan Biological
Indian Immunologicals
Segment by Type
Freeze-dried Powder
Liquid
Pre-exposure Prophylaxis
Post-exposure Prophylaxis
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Vero Cell Rabies Vaccines for Human report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Based on the culture medium, human rabies vaccines can be divided into vero cell vaccines, hamster kidney cell vaccines, chicken embryo cell vaccines and human diploid cell vaccines according to the culture medium. Developed countries in Europe and the United States mainly use human diploid cell vaccines , and China mainly uses second-generation vero cell vaccines.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Vero Cell Rabies Vaccines for Human market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bharat Biotech
Sanofi-Pasteur
Chengda Bio
Prcmise
Zhuoyi Biological
Ningbo Rongan Biological
Indian Immunologicals
Segment by Type
Freeze-dried Powder
Liquid
Segment by Application
Pre-exposure Prophylaxis
Post-exposure Prophylaxis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Vero Cell Rabies Vaccines for Human report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source